@ARTICLE{
author={Tobias Joshua,Kundi Michael,Garner-Spitzer E,Zielinski Christoph,Maglakelidze Marina,Andric Zoran G,Petrovic Z,Nagarkar R,Chawla T,Chong LO,Nixon B,Yavrom S,Ede NJ,Wiedermann Ursula},
year={2023},
title={HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome},
journal={ANNALS OF ONCOLOGY},
volume={34},
number={},
pages={S864-S864},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Tobias Joshua,Kundi Michael,Garner-Spitzer E,Zielinski Christoph,Maglakelidze Marina,Andric Zoran G,Petrovic Zeljko M,Nagarkar R,Chawla T,Chong LMO,Nixon B,Yavrom S,Ede NJ,Wiedermann Ursula},
year={2023},
title={HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2t-argeting peptide vaccine plus SOC chemotherapy in patients with HER2+advanced stomach cancer - correlation of the antibody responses and clinical outcome},
journal={ANNALS OF ONCOLOGY},
volume={34},
number={},
pages={S4-S4},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Maglakelidze Marina,Ryspayeva D,Andric Zoran G,Petrovic Zeljko M,Bulat IV,Nikolic Ivan V,Chawla T,Nagarkar R,Wiedermann Ursula,Blumenstein BA,Chong LMO,Ede NJ,Nixon B,Good AJ},
year={2022},
title={HERIZON overall survival results: A study of IMU-131, a HER2 targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2 overexpressing metastatic or advanced gastric/GEJ cancer},
journal={ANNALS OF ONCOLOGY},
volume={38},
number={9},
pages={S1460-S1460},
document_type={Meeting Abstract},
}